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Abstract
Background Persistent postoperative supraventricular
tachyarrhythmias (SVTs) increase cardiac burden and
aggravate cardiac hemodynamics. Therefore, for patients
in unstable conditions after surgery, prompt and sus-
tained control of heart rate is essential. The importance
of b-adrenoceptor antagonists (b-blockers) in controlling
such postoperative atrial fibrillation or atrial flutter has
been established, and the usefulness of ultra-short-acting
b1-blockers with high b1 selectivity has been suggested
based on their safety and efficacy under such
circumstances.
Objectives Our objectives were to evaluate the effec-
tiveness and safety of landiolol hydrochloride, an ultra-
short-acting b1-selective blocker, in the treatment of post-
operative SVT in patients with a high risk of myocardial
ischemia, or in patients after highly invasive surgery, in a
multicenter, randomized, double-blind, placebo-controlled,
group-comparative study.
Methods A total of 165 patients were randomly allocated
to three groups and received LM or MH doses of landiolol
hydrochloride or placebo. LM group: dose L (1-min load-
ing dose at a rate of 0.03 mg/kg/min, followed by a 10-min
infusion at 0.01 mg/kg/min) followed by dose M (1-min
loading at a rate of 0.06 mg/kg/min, followed by a 10-min
infusion at 0.02 mg/kg/min); MH group: dose M followed
by dose H (1-min loading dose at a rate of 0.125 mg/kg/
min, followed by a 10-min infusion at 0.04 mg/kg/min);
placebo (PP) group: dose P (1-min loading dose at a rate of
0 mg/kg/min, followed by a 10-min infusion at 0 mg/kg/
min) followed by another round of dose P. If the targeted
heart-rate reduction was not obtained at the end of the first
10-min infusion, the higher dose was started. The primary
endpoint was the percentage of patients who met the heart-
rate reduction criteria (C20 % reduction and \100 beats/
min). The safety endpoint was the incidence of adverse
events in each of the three groups.
Results The percentages of patients who met the heart-
rate reduction criteria (C20 % reduction and \100 beats/
min) were 0.0, 60.4, and 42.0 % in the PP, LM, and MH
groups, respectively. There were significant differences in
the LM and MH groups relative to the PP group, but there
was no significant difference between the LM and MH
groups. No significant difference was observed in the
incidence of adverse events among the three groups:
29.6 % in the PP group, 45.5 % in the LM group, and
43.1 % in the MH group.
Conclusion Landiolol hydrochloride is effective and safe
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1 Introduction
Persistent postoperative supraventricular tachyarrhythmias
(SVTs) increase cardiac burden and aggravate cardiac
hemodynamics. Hence, for patients in unstable conditions
after surgery, prompt and sustained control of heart rate is
essential. The importance of b-adrenoceptor antagonists
(b-blockers) in controlling such postoperative atrial fibril-
lation or atrial flutter has been established [1–5], and the
usefulness of ultra-short-acting b1-blockers with high b1
selectivity has been suggested based on their safety and
efficacy under such circumstances. Esmolol hydrochloride,
a prototype ultra-short-acting b1-blocker, has been shown
to be effective for postoperative SVT [3] and atrial fibril-




drochloride, is a newly developed ultra-short-acting selec-
tive b1-blocker with a short half-life (approximately 4 min) in
healthy human subjects [6], and its efficacy for tachyarrhyth-
mias during surgery has been confirmed [7].
In order to investigate the efficacy and safety of lan-
diolol hydrochloride on postoperative SVT requiring
emergency therapy, we conducted a multicenter, random-
ized, double-blind, placebo-controlled, three-group com-
parison study of landiolol hydrochloride in patients with
complications of hypertension and ischemic cardiac dis-
ease and in patients who had undergone highly invasive
sugary (cardiovascular surgery, resection of an esophageal
cancer, thoracotomy, and upper abdominal surgery).
2 Methods
This study, conducted in Japan between January 2001 and
December 2002, was designed as a central-registration,
prospective, multicenter, double-blind, randomized, paral-
lel-group study for the purpose of examining postoperative
SVT. The study was conducted in accordance with the
ethical principles of the Helsinki Declaration and Good
Clinical Practice. Written informed consent was obtained,
no later than the day before surgery, from all patients
enrolled in the study, and the study protocol was approved
by the Institutional Review Board of each study center.
2.1 Study Population
Patients aged 20 years or older who gave informed consent
in writing before surgery were selected from 38 study cen-
ters in Japan. The selected subjects included those who
developed postoperative tachycardia with an identifiable
cause that could be relieved, such as hypovolemia, and who,
even after treatment, still developed continuous SVT within
7 days postoperatively. Detailed selection criteria are shown
in Fig. 1. Patients were excluded from the study if they met
one of the following criteria: acute myocardial infarction
(within 1 month after onset), preoperative severe heart
failure (New York Heart Association [NYHA] functional
class III or higher), atrioventricular block (grade II or
higher), or sick sinus syndrome (including patients
implanted with a pacemaker); treatment with tri- and tetra-
cyclic psychotropic agents or oral b-blockers as concomitant
postoperative drugs; a blood pressure decrease (\90/
60 mmHg) during the run-in period; aspartate aminotrans-
ferase and alanine aminotransferase levels C2.5-fold higher
than the normal values at the study center (or C100 U/L) and
blood bilirubin C3.0 mg/dL within 2 weeks before surgery;
C25 mg/dL blood urea nitrogen (BUN) and C2 mg/dL
creatinine; the presence of drug hypersensitivity due to
allergy, pregnancy, or lactation; and administration of any
other investigational drug within 6 months prior to the start
of the study. Patients judged ineligible by the investigator for
any other reason were also excluded from the study.
2.2 Study Drugs and Study Design
Landiolol hydrochloride for injection (50 mg per vial) and a
matching placebo were used in the study. Subjects were
randomly allocated to the three groups: landiolol hydro-
chloride LM group, dose L (1-min loading dose at a rate
of 0.03 mg/kg/min, followed by a 10-min infusion at
0.01 mg/kg/min) followed by dose M (1-min loading at a rate
of 0.06 mg/kg/min, followed by a 10-min infusion at
0.02 mg/kg/min); MH group, dose M followed by dose H
(1-min loading dose at a rate of 0.125 mg/kg/min, followed
by a 10-min infusion at 0.04 mg/kg/min); and the placebo
(PP) group. Because no ultra-short-acting drug indicated for
postoperative SVT has been approved in Japan, placebo was
selected as a comparator. After confirming that the selection
criteria were met after surgery, four vials of the study drug
were dissolved in physiological saline. After a 1-min intra-
venous infusion, the drug was continuously infused intrave-
nously for 10 min using an infusion pump (the initial dose). If
the targeted heart-rate reduction (C20 % reduction from the
baseline heart rate and a heart rate of\100 beats/min) was
obtained after administration of the initial dose, the dose was
not increased. If the targeted heart-rate reduction was not
obtained, a second 1-min infusion and 10-min continuous
intravenous infusions were given at an increased dose. If the
targeted heart rate reduction was obtained during the period
of increased-dose administration, administration was com-
pleted. If hypotension (a systolic blood pressure [SBP]
decrease of C20 % from the baseline SBP and blood pressure
B90/60 mmHg) or marked bradycardia (a heart rate of
B60 beats/min) occurred, administration was discontinued.
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2.3 Concomitant Drugs and Therapies
Concomitant treatment with b-blockers, calcium antagonists
(diltiazem, verapamil, bepridil), other antiarrhythmic agents,
adrenergic drugs, and other investigational drugs were prohib-
ited throughout the run-in period and drug-administration per-
iod. For patients who had used a prohibited combination of these
drugs, we provided a washout period of at least twice the half-
life. No patients received intravenous administration of antiar-
rhythmic agents (propranolol, verapamil, diltiazem, procain-
amide, disopyramide, mexiletine, lidocaine, aprindine,
cibenzoline, or pilsicainide) before or during the study for a
period equal to two half-lives of the agent. Therapies that affect
heart rate were also prohibited during the run-in and drug-
administration periods. If dopamine/dobutamine had been
administered by continuous drip (dose rate \10 lg/kg/min)
before administration of the study drug, concomitant adminis-
tration at the same dose was permitted. Digitalis medicines used
before administration of the study drug were also permitted if the
pharmacological effect was confirmed to have reached a steady
state and the bradycardiac effect on the heart rate was constant.
2.4 Clinical Measurements
The following items were surveyed before initiation of the
study: demographic characteristics, disease names, surgical
techniques, date and time of surgery, type and onset time of
SVT, preoperative findings (electrocardiogram [ECG],
echocardiogram, other preoperative findings, NYHA clas-
sification of cardiac performance), complications of
hypertension, previous and concurrent myocardial infarc-
tions, previous and concurrent angina pectoris, other per-
tinent medical history, and other complications.
Heart rate, blood pressures (SBP/diastolic blood pres-
sure [DBP]), rate-pressure product (RPP), and ECG were
measured and calculated as efficacy parameters. ECG was
recorded using 12 leads within 1 month before surgery. At
least a II- or V5-lead ECG was recorded, and the RR
interval, PQ interval, QRS duration, QT interval, corrected
QT interval (QTc), and ST segment were measured. Lab-
oratory tests were performed to assess safety, and adverse
events were investigated for subjective symptoms and
objective findings.
2.5 Efficacy Endpoints
When the heart rate reduction relative to the baseline heart
rate was C20 % and the heart rate was \100 beats/min
after completion or discontinuation of administration, the
outcome was designated as ‘improved’. The primary end-
point, i.e., the improvement rate after the final dose, was
calculated by the following equation:
When patients with postoperative supraventricular tachyarrhythmias 
satisfied any of the below criteria, they were eligible for enrollment 
as study subjects
When patients satisfied criterion a) or b), below, they were then judged 
according to the subsequently listed criteria: 
a) Patients with a high risk of myocardial ischemia (preoperatively 
meeting one of the four following criteria): 
1) Hypertension as a complication*
2) Myocardial infarction as a complication† or a past history of 
myocardial infarction 
3) Angina pectoris as a complication†
4) Findings of ischemic changes‡ 
b) Patients who underwent cardiovascular surgery or other highly invasive 




 resection of an esophageal cancer 
 thoracotomy 
 upper abdominal surgery
HR of 120 beats/min for 1 minute or longer 
with abnormal ST segment on ECG§
HR of ≥ ≥
≥
120 beats/min for 3 
minutes or longer  in patients 
with sinus tachycardia
HR of 120 beats/min for 1 
minute or longer  in patients with 
supraventricular tachycardia other 
than sinus tachycardia
Fig. 1 Criteria for enrollment of patients in the study. *Patients for
whom the therapeutic drug could be confirmed, or patients with SBP
of 140 mmHg or higher and DBP of 90 mmHg or higher for C2 days,
with reference to WHO hypertension criteria. Patients for whom the
therapeutic drug could be confirmed. Patients with changes in ST
segment of 0.1 mV or more (including a decrease in ST segment by
0.05 mV or more in a Master 2-step test), an abnormal Q wave,
negative T wave, U wave, or other abnormal findings related to
ischemic changes on the ECG in a resting state or after exercise; or
patients with LVH, abnormal wall movement, or a right ventricular/
right atrial load on echocardiography in a test performed within
1 month of surgery. §Patients with an abnormal change (C0.1 mV) in
ST segment from the value on ECG at rest and with an ST segment of
C?0.1 mV or B-0.1 mV. kVariation in HR immediately before
administration is less than 10 % of that recorded 1 or 3 min earlier.
DBP diastolic blood pressure, ECG electrocardiogram, HR heart rate,
LVH left ventricular hypertrophy, SBP systolic blood pressure
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Improvement rate after the final dose ð%Þ
¼ ½fðnumber of patients judged ‘improved’ after the initial doseÞ
þ ðnumber of patients judged ‘improved’ after the
increased dose/the number of patients analyzedÞg  100:
In addition, the cumulative improvement rate, heart rate,
blood pressure, RPP, and ECG parameters were evaluated
as secondary endpoints. The cumulative improvement rate
was calculated by the following equation:
Cumulative improvement rate (%)
¼ ½1  f(the number of patients who were not judged
‘improved’ at the initial dose)g =
ðthe number of patients analyzed at the initial dose)
 fðthe number of patients who were not judged
‘improved’ at the increased doseÞ=
ðthe number of patients analyzed at the
increased doseÞg  100:
2.6 Safety Variables
The incidence and nature of adverse events and adverse
drug reactions, as well as abnormal changes in laboratory
data, were investigated in comparison with the PP group.
2.7 Sample Size
According to the results of a late phase II study for post-
operative SVT, improvement rates after the final dose were
hypothesized to be 13.3, 51.1, and 73.3 % for the PP, LM,
and MH groups, respectively. Chi-square tests were con-
ducted for statistical analyses, aiming at a two-tailed sig-
nificance level of 0.05 with a statistical power of 0.9.
Multiplicity was adjusted by the Bonferroni correction,
with a two-tailed significance level of 0.025 per test. To
achieve this level of statistical precision, the necessary
number of cases (taking dropouts and withdrawals into
account) was determined to be 55 per group, leading to a
total of 165 cases among the three groups.
2.8 Statistical Analysis
Statistical analyses were performed using SAS Version
6.12 or 8.2. For comparisons of demographic variables and
patient characteristics, Fisher’s exact test or the Kruskal–
Wallis test was used where appropriate. The significance
level was set at 0.05 (two-tailed). The Chi-square test was
used to evaluate differences in improvement rate after the
final dose (the primary endpoint) between the PP and LM
groups and between the PP and MH groups. The signifi-




bpm beats per minute, LM group
dose L (1-min loading dose at a
rate of 0.03 mg/kg/min,
followed by a 10-min infusion
at 0.01 mg/kg/min) followed by
dose M (1-min loading dose at a
rate of 0.06 mg/kg/min,
followed by a 10-min infusion
at 0.02 mg/kg/min), MH group
dose M followed by dose H (1-
min loading dose at a rate of
0.125 mg/kg/min, followed by a
10-min infusion at 0.04 mg/kg/
min), PP group dose P (1-min
loading dose at a rate of 0 mg/
kg/min, followed by a 10-min
infusion at 0 mg/kg/min)
followed by another round of
dose P, RPP rate pressure
product, SBP systolic blood
pressure
* By Fisher’s exact test
(Freeman and Halton test)
 By Kruskal–Wallis test
Background factor Treatment group Test result
PP group LM group MH group
Patients (n) 50 50 51
Gender [n (%)]
Male 37 (74.0) 39 (78.0) 36 (70.6) p = 0.7153*
Female 13 (26.0) 11 (22.0) 15 (29.4)
Age (years) 64.8 ± 10.5 63.6 ± 11.9 62.2 ± 9.6 p = 0.2972
Type of supraventricular tachyarrhythmias [n (%)]
Sinus tachycardia 27 (54.0) 33 (66.0) 34 (66.7) p = 0.3631*
Paroxysmal atrial fibrillation 23 (46.0) 15 (30.0) 13 (25.5)
Paroxysmal atrial flutter 0 (0.0) 2 (4.0) 3 (5.9)
Paroxysmal supraventricular
tachycardia
0 (0.0) 0 (0.0) 1 (2.0)
Site of surgery [n (%)]
Cardiovascular surgery 32 (64.0) 33 (66.0) 32 (62.7) p = 0.7325*
Upper abdominal surgery 3 (6.0) 2 (4.0) 0 (0.0)
Resection of an esophageal cancer 11 (22.0) 12 (24.0) 16 (31.4)
Thoracotomy 3 (6.0) 3 (6.0) 2 (3.9)
Total dosage of dopamine/
dobutamine (lg/kg/min)
5.631 ± 4.060 5.123 ± 4.299 4.927 ± 4.690 p = 0.3697
Baseline heart rate (beats/min) 137.1 ± 14.5 132.8 ± 13.9 131.8 ± 10.2 p = 0.1642
Baseline SBP (mmHg) 132.7 ± 27.4 127.0 ± 19.6 127.1 ± 24.3 p = 0.4693
Baseline RPP (bpm  mmHg) 18,196 ± 4,491 16,784 ± 2,570 16,690 ± 3,086 p = 0.2362
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Bonferroni inequality. Secondary endpoints were analyzed
by Dunnett’s multiple comparison and the Chi-square test.
Significance was defined as p B 0.05 (two-tailed).
3 Results
3.1 Patient Characteristics
A total of 165 patients were enrolled in the study and
randomly assigned to the PP group (54 patients), LM group
(56 patients), and MH group (55 patients). Of these
patients, five were completely excluded from any analyses,
including safety evaluation, due to the absence of tachy-
cardia prior to administration of the study drug. The
remaining 160 patients are henceforth referred to as the
‘safety patients’ (PP group, n = 54; LM group, n = 55;
MH group, n = 51). Protocol deviations and other factors
led to exclusion of nine patients (PP group, n = 4; LM
group, n = 5) from the full-analysis set (FAS), and 22
patients (PP group, n = 8; LM group, n = 9; MH group,
n = 5) from the per-protocol set (PPS). Hence, 160 safety
patients were used for safety analysis, and 151 ‘FAS
patients’ (PP group, n = 50; LM group, n = 50; MH
group, n = 51) and 138 ‘PPS patients’ (PP group, n = 46;
LM group, n = 46; MH group, n = 46) were evaluated.
In the FAS patients, no significant differences in
demographic characteristics were observed among the
three groups (Table 1).
3.2 Primary Endpoint for Efficacy
The improvement rate after the final dose is shown for each
group in Table 2. In the FAS patients—the primary pop-
ulation used in the efficacy analysis—the improvement rate
was significantly higher in the LM group (60.4 %) and the
MH group (42.0 %) than in the PP group (0.0 %) (Chi-
square test with Bonferroni correction, p = 0.0001). No
significant difference was observed between the LM and
MH groups. Similar results were obtained in the PPS
patients.
3.3 Secondary Endpoints for Efficacy
3.3.1 Cumulative Improvement Rate within Each Group
In the FAS patients, the cumulative improvement rates at
the initial and increased doses were as follows: PP, 0.0 and
0.0 %; LM, 8.3 and 61.6 %; and MH, 22.0 and 43.1 %.
Thus, the cumulative improvement rate increased with dose
in both the LM and the MH groups. The results obtained
from analysis of the cumulative improvement rates were
consistent with the findings based on improvement rates
after the final dose. Similar results were obtained in the
PPS patients.
3.3.2 Tachycardia Improvement Rate after the Initial Dose
In the FAS patients, the tachycardia improvement rates
after the initial dose were 0.0, 8.3, and 22.0 % in the PP
group (initial dose: placebo [dose P]), LM (initial dose:
dose L), and MH (initial dose: dose M) groups, respec-
tively. The improvement rate was significantly higher with
dose M than with dose P (Chi-square test, p = 0.0018),
although no significant difference was observed between
doses P and L or between doses L and M. Similar results
were obtained in the PPS patients.
3.3.3 Heart Rate
Heart rate time curves of the FAS patients are shown in
Fig. 2. The percentage changes in heart rate from baseline
(mean ± standard deviations) were -1.56 ± 6.80,
-15.02 ± 7.41, and -13.68 ± 10.57 % in the PP, LM,
and MH groups, respectively, following the initial dose.
After completion of administration (or at discontinuation),
Table 2 Improvement rate after the final dose
Treatment group Improved Not improved Improvement rate
[% (95 % CI)]
Superiority relative
to the PP groupa
Dose-dependency between
LM and MH groupsb
PP group (N = 48) 0 48 0.0 (0.0–0.0)
LM group (N = 48) 29 19 60.4 (46.6–74.3) PP vs. LM
p = 0.0001




Refer to Table 1 for treatment group definitions
CI confidence interval
a Chi-square test; significance was defined as p \ 0.025 (two-tailed) based on Bonferroni correction
b Chi-square test; significance was defined as p \ 0.05 (two-tailed)
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the percentage changes (mean ± standard deviations) were
-2.42 ± 7.89, -23.32 ± 7.96, and -18.93 ± 10.03 % in
the PP, LM, and MH groups, respectively. Hence, after all
dose intervals, a significant reduction in heart rate was
observed in the LM and MH groups, compared with that in
the PP group (Dunnett test, p = 0.0001). Regarding tem-
poral changes in the heart rate, a significant reduction was
observed within 6 min after initiation of administration in
the LM and MH groups, compared with that in the PP
group (Dunnett test: LM group, p = 0.0002; MH group,
p = 0.0001), and the maximum bradycardiac effect was
observed immediately after completion of administration
(or at discontinuation) in the LM group, and 5 min after
completion of administration (or at discontinuation) in the
MH group. Heart rate increased with time thereafter, and
no statistical differences among the three groups were
observed 30 min after completion of administration.
3.3.4 Blood Pressure
The changes in SBP from baseline were -4.2 ± 12.9,
-11.2 ± 11.6, and -5.9 ± 14.1 mmHg in the PP, LM,
and MH groups, respectively, after the initial dose. The
changes in DBP were -1.4 ± 6.8, -4.2 ± 5.6, and
-2.5 ± 6.0 mmHg in the PP, LM, and MH groups,
respectively. After completion of administration (or at
discontinuation), the changes in SBP from baseline were
-6.2 ± 18.2, -15.7 ± 14.2, and -9.7 ± 14.7 mmHg in
the PP, LM, and MH groups, respectively. Changes in DBP
were -1.3 ± 9.3, -5.5 ± 6.4, and -3.6 ± 6.0 mmHg in
the PP, LM, and MH groups, respectively.
The values of SBP and DBP were significantly
decreased in the LM group at all dose intervals, compared
with those in the PP group (Dunnett test: after the initial
dose, p = 0.0147 for SBP and p = 0.0428 for DBP; after
completion of administration (or at discontinuation),
p = 0.0072 for SBP and p = 0.0112 for DBP), but no
significant changes were observed in the MH group.
The changes in SBP and DBP in the FAS patients are
shown in Fig. 3. Decreases in SBP and DBP were observed
6 min after initiation of administration in the LM and MH
groups. After completion of administration, blood pressure
increased with time, and the values were similar among the
three groups 30 min after completion of administration.
3.3.5 Rate Pressure Product
In the FAS patients, baseline RPPs were 18,196 ± 4491,
16,784 ± 2570, and 16,690 ± 3,086 beats/min  mmHg in
the PP, LM, and MH groups, respectively, i.e., the values
were higher than 15,000 beats/min  mmHg in all groups.
After completion of administration (or at discontinuation),
significant decreases in RPP were observed in the LM
group (11,255 ± 2,106 beats/min  mmHg) and the MH
group (12,503 ± 3,206 beats/min  mmHg), compared
with that in the PP group (16,994 ± 4,148 beats/
min  mmHg) (Dunnett test, p = 0.0001).
In the RPP time-course, significant decreases were noted
6 min after initiation of administration in the LM and MH
groups, compared with the PP group (Dunnett test: LM
group, p = 0.0007; MH group, p = 0.0064), and the
maximum change was observed immediately after
Pre 1 Pre 2 6 11 17 22 C 5 10 15 30 60
(min) (min)
Number of patients
PP group 49 50 50 49 50 48 48 50 50 50 49 48
LM group 50 50 49 49 36 27 48 48 49 50 49 49







































Fig. 2 Time course of
percentage change in heart rate
(mean ± standard deviation).
Pre 1 measurement of heart rate
3 min (sinus tachycardia),
1 min (other than sinus
tachycardia), or 1 min
(tachycardia with abnormal ST
segment) before initiation of
infusion, Pre 2 measurement of
heart rate conducted
immediately before initiation of
infusion, C sum of the result
immediately after completion of
infusion plus the results at
discontinuation of infusion.
Refer to Table 1 for treatment
group definitions. *Dunnett test;
significance was defined as
p \ 0.05 (two-tailed)
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completion of administration (or at discontinuation) in the
LM group, and 5 min after completion in the MH group, as
observed for the heart rate. RPP increased with time
thereafter, and no differences relative to the PP group were
detected 30 and 15 min after completion of administration
in the LM and MH groups, respectively.
3.3.6 ECG Parameters
The ECG parameters are shown in Table 3. Compared with
the PP group, the RR interval, PQ interval, QRS duration,
and QT interval were significantly prolonged after comple-
tion of administration (or at discontinuation) in both the LM
and the MH groups (Dunnett test: RR interval, p = 0.0001;
PQ interval, p = 0.0160 and p = 0.0015, respectively; QRS
duration, p = 0.0483; QT interval, p = 0.0001). No signif-
icant changes were observed in the ST segment or QTc.
3.3.7 Investigation of Subpopulations
The improvement rates after the final dose, stratified by
background factors in the FAS population, are shown in
Table 4. In the group stratified based on the baseline heart
rate, the improvement rate decreased with an increase in
the baseline heart rate. No meaningful bias was observed in
the other stratifications.
3.4 Safety
3.4.1 Incidences of Adverse Events and Adverse Drug
Reactions
Sixteen of 54 patients (29.6 %) in the PP group, 25 of 55
patients (45.5 %) in the LM group, and 22 of 51 patients
(43.1 %) in the MH group experienced adverse events.
Among these events, those in five patients (9.3 %) of the
PP group, 13 patients (23.6 %) of the LM group, and 10
patients (19.6 %) of the MH group were judged by inves-
tigators to be related to administration of study drug, i.e., to
be adverse drug reactions (ADRs). Although the incidences
of adverse events and ADRs were higher in the LM and
MH groups than in the PP group, no significant differences
were observed among the three groups.
3.4.2 Subjective Symptoms and Objective Findings
There were 28 adverse events, based on subjective symp-
toms and objective findings, in 11 patients of the PP group,
21 events in 13 patients of the LM group, and 25 events in
12 patients of the MH group. Among these, two events in
two patients of the PP group, six events in six patients of
the LM group, and five events in four patients of the MH
group were judged to be ADRs, as summarized in Table 5.
All ADRs in all three groups were related to the cardio-
vascular system, with the most frequent ADR being
hypotension (B90/60 mmHg). One event of ventricular
extrasystoles occurred in one patient of the PP group.
Of the six cases of hypotension in the LM group, the
severity was mild in four patients, moderate in one patient,
and severe in one patient. Moderate and severe cases of
hypotension developed after initiation of the increased dose
(dose M). Two cases of mild hypotension remitted without
any action being taken, whereas the four other cases were
resolved by discontinuation of study drug administration
(three cases) and/or treatment with blood transfusion and
plasma protein fraction (two cases). There were three mild
and two moderate hypotension cases in the MH group. One
moderate case developed after the initial dose (dose M),
Pre 1 Pre 2 6 11 17 22 C 5 10 15 30 60
(min) (min)
Number of patients
PP group 49 50 50 50 50 49 49 50 50 50 49 48
LM group 50 50 49 49 36 27 48 48 49 50 49 49

























PP group SBP PP group DBP
LM group SBP LM group DBP
MH group SBP MH group DBP
* * * * *
****
Fig. 3 Time course of changes
in blood pressure
(mean ± standard deviation).
Pre 1 measurement of blood
pressure 3 min (sinus
tachycardia), 1 min (other than
sinus tachycardia), or 1 min
(tachycardia with abnormal ST
segment) before initiation of
infusion, Pre 2 measurement of
blood pressure conducted
immediately before initiation of
infusion, C sum of the result
immediately after completion of
infusion plus the results at
discontinuation of infusion, SBP
systolic blood pressure, DBP
diastolic blood pressure. Refer
to Table 1 for treatment group.
*Dunnett test; significance was
defined as p \ 0.05 (two-tailed)
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and another moderate case developed 7 min after initiation
of the increased dose (dose H). All three cases of mild
hypotension remitted without any action being taken, and
the two cases of moderate hypotension were resolved by
discontinuation of study drug administration (two cases)
and/or treatment with procainamide hydrochloride (one
case).
3.4.3 Laboratory Observations
Six events were judged to be ADRs based on abnormal
changes in laboratory values in three patients of the PP
group, 15 such events in seven patients of the LM group,
and 14 such events in six patients of the LM group. The
increased laboratory values were mainly related to hepa-
tobiliary disorders. All abnormal changes in laboratory
values were resolved or remitted without any action being
taken.
4 Discussion
The mechanism underlying postoperative SVT is thought
to be related to the action of catecholamines, resulting from
increased adrenergic drive caused by various stresses dur-
ing and after surgery [8–11]. In emergency treatment and
acute management of postoperative SVT, the use of ultra-
short-acting b1-blockers allows rapid onset of drug effect,
as well as rapid dissipation of the effects when drug infu-
sion is completed or when adverse events develop.
Therefore, esmolol hydrochloride is very useful, and is
effective for treatment of postoperative tachyarrhythmias
[3] and atrial fibrillation and atrial flutter after open-heart
surgery [4]. However, esmolol can be directly cardiode-
pressive and can cause hypotension and even congestive
heart failure, limiting its usefulness [12–15]. Landiolol
hydrochloride, a new ultra-short-acting b1-blocker, has a
higher cardioselectivity (b1/b2 = 255) [16] and a shorter
Table 4 Improvement rates
after the final dose, stratified by
background factors
Refer to Table 1 for treatment
group definitions
bpm beats per minute
Stratification factor Number of patients (improvement rate [%])
PP group LM group MH group
Improved Total Improved Total Improved Total
Total 0 48 (0.0) 29 48 (60.4) 21 50 (42.0)
Age (years)
21–64 0 18 (0.0) 16 23 (69.6) 10 25 (40.0)
65–86 0 30 (0.0) 13 25 (52.0) 11 25 (44.0)
Type of supraventricular tachyarrhythmias
Sinus tachycardia 0 27 (0.0) 19 32 (59.4) 17 34 (50.0)
Others 0 21 (0.0) 10 16 (62.5) 4 16 (25.0)
Site of surgery
Cardiac vascular surgery 0 30 (0.0) 21 33 (63.6) 15 32 (46.9)
Resection of an esophageal cancer 0 11 (0.0) 6 10 (60.0) 5 15 (33.3)
Thoracotomy 0 3 (0.0) 1 3 (33.3) 0 2 (0.0)
Amount of dopamine/dobutamine used (lg/kg/min)
Not used 0 6 (0.0) 2 6 (33.3) 3 10 (30.0)
0.50–5.00 0 21 (0.0) 15 24 (62.5) 8 22 (36.4)
5.01–10.00 0 17 (0.0) 9 14 (64.3) 7 13 (53.8)
10.01–20.00 0 4 (0.0) 3 4 (75.0) 3 5 (60.0)
Baseline heart rate (bpm)
120–129 0 19 (0.0) 19 25 (76.0) 15 25 (60.0)
130–139 0 10 (0.0) 7 13 (53.8) 3 14 (21.4)
140–189 0 19 (0.0) 3 10 (30.0) 3 11 (27.3)
Baseline systolic blood pressure (mmHg)
92–139 0 31 (0.0) 19 34 (55.9) 14 35 (40.0)
140–219 0 17 (0.0) 10 14 (71.4) 7 15 (46.7)
Baseline RPP (bpm  mmHg)
11,280–16,999 0 21 (0.0) 15 26 (57.7) 12 31 (38.7)
17,000–35,916 0 27 (0.0) 14 22 (63.6) 9 19 (47.4)
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elimination half-life (4 min in healthy subjects) [6] than
esmolol.
The results of this study demonstrate that landiolol
hydrochloride is significantly more effective than placebo,
based on a primary endpoint of the improvement rate after
the final dose (the percentage of patients with C20 %
reduction in the heart rate from the baseline heart rate and a
heart rate of \100 beats/min after completion of adminis-
tration). No significant difference was observed in the
improvement rate after the final dose between the two
landiolol hydrochloride-treated groups, although the rate
was higher in the LM group than in the MH group. Based
on investigations of subpopulations, only the baseline heart
rate had a major influence on the improvement rate after
the final dose. Therefore, the higher improvement rate after
the final dose in the LM group cannot be clearly explained
by patients’ background factors, and might be due to the
influence of individual differences among the patients in
the two groups. The response rate of esmolol in the post-
operative SVT was different between the clinical study. We
speculate that the absence of a significant difference in the
dose response between the LM and MH groups is related to
the fact that the postoperative systemic conditions,
including hemodynamics, of the patients were highly
unstable, and that this instability largely depended on
individual patient characteristics; therefore, the response
rate of the drug, i.e., the effective dose required to lower
heart rate, may have differed markedly among individual
patients. However, an increased dose was confirmed to be
effective in both the LM and the MH groups. Conse-
quently, we believe that it is appropriate to administer this
drug in a regimen in which the dose is gradually increased
from low dosage (dose L) to high dosage (dose H). Mul-
tiple factors may have contributed to this, including dif-
ferences in patient demographics, diagnoses, clinical
conditions, and, in particular, the types of arrhythmias [17].
Because the criterion ‘‘less than 100 beats/min’’ was used
as one of the criteria for improvement, the improvement
rate decreased with an increase in the baseline heart rate.
The RPP reflects myocardial oxygen consumption and is
used as an index of cardiac load. In this study, the baseline
RPP was C15,000 beats/min  mmHg in all three groups.
There is a positive correlation between the incidence of ST-
segment depression in an ECG, which reflects myocardial
ischemia, and RPP in patients with RPP of C12,000 beats/
min  mmHg during coronary-artery bypass graft surgery
[18]; an RPP of 12,000 beats/min  mmHg is generally
targeted for initiation of therapy for prevention of myo-
cardial ischemia in the perioperative period. In both the
LM and the MH groups, landiolol hydrochloride
Table 5 List of adverse drug reactions (subjective symptoms/objective findings)
Treatment group Content Onset Severity Action taken Clinical course







PP Hypotension 27 Placebo (post) Mild No action taken Resolved (5 min)
Ventricular extrasystoles 10 Placebo Mild No action taken Resolved (1.2 h)
LM Hypotension 11 Dose L Mild No action taken Resolved (15 min)
Hypotension 19 Dose M Severe Discontinuation of study drug Remitted (5 min)
Hypotension 20 Dose M Mild Discontinuation of study drug Remitted (15 min)





Hypotension 26 Dose M (post) Mild No action taken Resolved (5 min)
Hypotension 36 Dose M (post) Moderate Administration of plasma
protein fraction
Remitted (15 min)
MH Hypotension 10 Dose M Mild No action taken Remitted (31 min)
Hypotension 11 Dose M Mild No action taken Remitted (6 min)




Hypotension 18 Dose H Moderate Discontinuation of study drug Resolved (1 h)
Hypotension 28 Dose H (post) Mild No action taken Resolved (25 min)
Refer to Table 1 for treatment group definitions
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significantly decreased RPP to approximately 12,000 beats/
min  mmHg, suggesting that the potency of the study drug
was sufficient for avoidance of myocardial ischemia.
Regarding safety, hypotension (B90/60 mmHg) was the
most frequent ADR. However, because this hypotension
was resolved or remitted rapidly (within 5 min to 1 h after
onset), either without treatment, by discontinuation of
study drug administration, or by treatment such as a blood
transfusion, we concluded that hypotension could be con-
trolled by appropriate adjustment of the dose or by other
treatment. We observed no ADRs based on b2-blocking
action, including asthma, peripheral vascular system dis-
orders, or other reactions, reflecting the high b1-selectivity
of landiolol hydrochloride.
Esmolol hydrochloride has been compared with placebo
in a double-blind controlled study in SVT patients with
heart rates of 120 beats/min or higher [19]. The improve-
ment rate caused by esmolol hydrochloride was 66 %,
based on a 20 % or greater heart rate reduction and a heart
rate of less than 100 beats/min; the rate of recovery of
sinus rhythm was 6 % [19]. In this study, the improvement
rate in the landiolol hydrochloride-treated group was 62 %,
a bradycardiac effect similar to that of esmolol hydro-
chloride. Regarding the relative safety of esmolol hydro-
chloride and landiolol hydrochloride, the incidence of
hypotension (B90/50 mmHg) at the effective dose of
esmolol hydrochloride was reported by one study to be
52.4 % (13 of 24 patients) in patients with postoperative
tachyarrhythmias [3]. By contrast, the incidence of hypo-
tension with landiolol hydrochloride in this study was only
9.4 % (10 of 106 patients). Nonclinical comparison studies
between esmolol hydrochloride and landiolol hydrochlo-
ride have been conducted in vitro and in vivo, and con-
flicting data regarding the half-lives and potencies of these
drugs are available. Sasao et al. [20] reported that landiolol
hydrochloride exhibited more potent negative chronotropic
effects without a reduction in blood pressure relative to
esmolol hydrochloride; furthermore, esmolol hydrochlo-
ride produced a dose-dependent decrease in mean arterial
pressure in a rabbit model. Although there are currently no
clinical data that directly compare esmolol hydrochloride
and landiolol hydrochloride, the data obtained from this
study appear to be similar to the results obtained in the
rabbit model. This study had the following limitations: the
study was conducted between January 2001 and December
2002 but these data could not be published earlier because
of an internal company policy; although it would have been
ideal to conduct a direct comparison with another short-
acting beta-blocker such as esmolol, this could not be
achieved as esmolol was not available in Japan at the time
of this study; as landiolol is only available for clinical use
in Japan, our results are of limited value to international
readers.
In conclusion, landiolol hydrochloride can be used
safely, and a sufficient therapeutic effect can be obtained
by administration at an initial dose M, followed by an
increase to dose H if the bradycardiac effect on postoper-
ative SVT is insufficient, in patients with a high risk of
myocardial ischemia and in patients who have undergone
highly invasive surgery. Landiolol hydrochloride is supe-
rior in terms of controllability and safety, because of both
the rapid attainment of a bradycardiac effect after initiation
of administration and the rapid dissipation of this effect
after administration is terminated. Thus, landiolol hydro-
chloride exhibits potency similar to that of esmolol
hydrochloride, and has improved safety characteristics.
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Appendix
Trial members and Investigators and Study Sites are as
follows.
Trial members
Jun Takezawa, Chikuma Hamada, Hiroyuki Iinuma, Nob-
uyuki Taenaka
Investigators and Study Sites
Doi Hirosato, Cardiovascular Center Hokkaido Ohno
Hospital; Fumiyuki Okamoto, Teine Keijinkai Hospital;
Hironori Ishihara, Hirosaki University School of Medicine
& Hospital; Koukichi Andoh, Sendai City Hospital; Mit-
sukazu Gotoh, Fukushima Medical University Hospital;
Kohjirou Urazumi, Ohta Atami Hospital; Hideaki Nakano,
Tokyo Medical University Kasumigaura Hospital; Nobu-
hiro Saruki, Gunma Prefectural Cancer Center; Shunei
Kyo, Saitama Medical University Hospital; Junzo Takeda,
Keio University Hospital; Miyuki Yokota, Cancer Institute
Hospital; Hideaki Miyamoto, Juntendo University Hospi-
tal; Takashi Hirotani, Tokyo Saiseikai Central Hospital;
Yoshihiro Yagishita, International Medical Center of
Japan; Kozo Hashimoto, Fujisawa City Hospital; Toshio
Konishi, Yokohama Rosai Hospital; Hiroshi Kanazawa,
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Niigata City General Hospital; Shigetaka Kasuya, Tac-
hikawa Medical Center; Tsutsumi Yasushi, Fukui Cardio-
vascular Center; Kousuke Baba, Hokushin General
Hospital; Takahiro Takemura, National Nagano Hospital;
Yoshito Shiraishi, Shizuoka General Hospital; Hiroshi
Noguchi, Aichi Medical University Hospital; Tsutomu Ohi,
Matsusaka Central General Hospital; Shinichi Nishi, Osaka
City University Hospital; Hisao Kishida, Osaka Medical
College Hospital; Masahiro Shinozaki, Wakayama Medical
University Hospital; Hiroshi Katayama, Okayama Univer-
sity Hospital; Tatsuhiko Komiya, Kurashiki Central Hos-
pital; Tsuyoshi Maekawa, Yamaguchi University Hospital;
Yoshitoyo Miyauchi, Tokuyama Central Hospital; Yas-
utoshi Matayoshi, Yamaguchi Prefectural Central Hospital;
Arifumi Kohyama, Tokushima Red Cross Hospital; Ka-
tsuhiro Seo, Kokura Memorial Hospital; Kazuhisa Matsu-
da, Saiseikai Fukuoka General Hospital; Koji Sumikawa,
Nagasaki University Hospital; Shigenori Yoshitake, Oita
Medical University Hospital; Yuichi Kanmura, Kagoshima
University Medical and Dental Hospital.
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